consolid come
need new antibiot
antibiot one commonli prescrib class drug estim global market billion
half us hospit patient receiv least one antibiot cours stay result
estim million day in-pati antibiot therapi us widespread use antibiot along
new innov market led increas rate antibiot resist across multipl bacteri strain
cdc estim multi-drug resist mdr strain account million infect death
annual us
need new antibiot address mdr bacteria especi mrsa gram-neg strain bacteria
protect outer cell membran commonli use antibiot gener version drug
blockbust world lead pharmaceut compani earli antibiot
develop declin significantli past three decad larg pharma compani shift away acut
care fda averag three new antibiot approv per year rate fell two annual
approv sinc fda approv averag one new antibiot per year
exhibit timelin antibiot approv us sinc
antibiot approv fda
last wave consolid
last round consolid within antibiot sector occur juli decemb
seven signific acquisit licens deal announc total billion up-front
payment billion potenti mileston activ coincid concentr new antibiot
approv fda nine month period may februari fda approv five new
antibiot five differ compani four compani develop product cubist zerbaxa
durata dalvanc forest avycaz triu sivextro acquir fifth
medicin orbactiv recent complet sale antibiot portfolio
believ ineffici single-product antibiot compani abil leverag singl
hospit sale forc sell multipl antibiot help drive consolid within antibiot sector
ten new antibiot approv fda sinc develop eight differ compani
ownership four allergan avycaz dalvanc teflaro johnson johnson sirturo melinta
baxdela orbactiv vabomer merck dificid sivextro zerbaxa
million
cempra/melinta deal all-stock reverse-merg melinta sharehold own combin compani
 acquir ex-north american right teflaro avibactam-bas antibiot includ avycaz
compani file gabelli compani estim
recent acquisit licens deal antibiot
potenti new antibiot approv us
antibiot landscap appear similar begin june fda could potenti
approv six new antibiot six differ compani one year time-frame one compani
shionogi market drug influx new approv along ineffici single-
product compani could drive anoth wave consolid within antibiot landscap
compani file gabelli compani estim
given slow uptak recent antibiot launch believ difficult multipl compani justifi
cost build commerci oper singl antibiot base data symphoni health
solut five antibiot launch averag approxim sale second year
market even best-perform product avycaz fail reach second year consolid larger
pharma player merger among smaller pure-play compani would allow cost singl commerci sale
oper spread multipl product portfolio two product could potenti cover cost
commerci rep hospit sale within two year also reduc neg impact
specif antibiot under-perform market expect estim combin two antibiot one
infrastructur could yield sale market cost synergi million
quarterli sale recently-launch antibiot
expect current valuat also encourag consolid within sector histor antibiot
valu approxim million phase asset twice newli approv drug recent
acquisit significantli level though natur transact cempra/melinta
revers merger melinta/medicin co deal facilit capit deerfield like contribut skew
valuat recent two pure-play antibiot compani tetraphas cempra reach market
capit billion today six pure-play antibiot compani coverag combin market
capit billion basket compani asset includ
melinta orbactiv
minocin yoy revenu
melinta vabomer baxdela
three antibiot pend fda achaogen plazomicin
tetraphas eravacyclin paratek omadacyclin plu
royalti fourth paratek sarecyclin acn
one pre-nda antibiot motif iclaprim success
lefamulin success complet first two
studi anoth
pipelin includ three phase one phase ii three
combin net cash million bring total
enterpris valu basket billion
buy basket
investor buy basket antibiot compani like reward see anoth round
consolid approach spread risk across multipl asset reflect belief antibiot sector
whole under-valued favorit individu name sector achaogen paratek buy
recommend believ achaogen plazomicin strongest phase data packag late-stag
recent approv antibiot could becom part new standard care regimen treat sever cre
infect paratek omadacyclin broadest applic once-daili broad spectrum oral-to-iv antibiot
cap absssi along develop program cuti enter phase ii
view motif nabriva tetraphas like acquisit target given market capit
market size opportun timelin approv three compani market capit
million enterpris valu approxim million mtfb nbrv million ttph
buy recommend nabriva tetraphas hold recommend motif
melinta offer portfolio four approv drug larg de-risk term clinic regulatori event
beyond phase cap data baxdela hold recommend mlnt
achaogen headquart south san francisco ca clinic stage pharmaceut compani develop
plazomicin novel aminoglycosid antibiot plazomicin complet phase studi treatment
carbapenem-resist enterobacteriacea infect complic urinari tract infect cuti
compani went public march ipo price per share
plazomicin current pend fda pdufa date june compani announc fda
hold advisori committe meet adcom may prior make decis approv upcom
adcom fda decis primari catalyst achaogen
fda adcom fda adcom discuss plazomicin may set time-frame
compani next catalyst expect key point discuss around data studi
patient includ mortal data propos indic use bloodstream infect bsi
believ total data could support label claim though caution signific
risk neg adcom vote sinc data come small number patient plazomicin
colistin cohort bsi pre-specifi popul cohort includ bsi hap/vap
high probabl approv believ adcom posit even doesnt go akao way
data epic studi enough support approv cuti current model likelihood
approv june manufactur issu appear resolv favor label
includ data studi would provid greater upsid would still expect see off-label usag
bsi patient without label given strength data avail
hospit physician scientif public high mortal rate patient current
buyer seller view achaogen like buyer seller within antibiot sector
consid plazomicin phase data strongest recent approv late-stag antibiot
view backbon product premium price point compani also pipelin
c-scape expect enter phase cuti later year sever preclin program across
million except per share
compani file gabelli compani estim
continu recommend achaogen one favorit name antibiot sector compani clear
near-term catalyst upcom adcom/pdufa date plazomicin believ combin
therapi includ plazomicin could becom new standard care american treat cre
infect annual expect annual sale plazomicin surpass million akao trade
discount pmv per share
fda advisori committe meet may plazomicin
fda pdufa date june plazomicin
ema submiss plazomicin
plazomicin launch us
initi pivot phase studi c-scape
million except per share
current market discount pmv
net present valu feder nol carryforward
 after-tax payment buy warrant option pmv
compani file gabelli compani estim
melinta headquart new ct pharmaceut compani focus develop sale
antibiot compani four approv product includ two baxdela vabomer approv
compani went public novemb revers merger cempra
acquisit medicin compani anti-infect portfolio posit melinta one lead
commerci antibiot compani mlnt two product launch phase baxdela vabomer two older
product orbactiv minocin iv million revenu growth
earli day new launch mlnt nearli complet integr mdco busi
compani approxim sale rep plu medic scienc liaison sell us hospit
market vabomer launch octob face formulari reject despit premium
price wac place account baxdela launch februari
avail million cover live tier statu prior author mlnt price oral
dose wac iv dose wac provid addit financi incent
target profit manag believ melinta reach run-rat cash flow
profit end oper expens guidanc million exclud
potenti mileston cost could reduc time assum stabl sg expens
reduct believ compani could ebitda posit approxim million
revenu estim revenu grow flow profit
depend compani capit structur go forward
buyer seller melinta activ buyer antibiot sector expect compani
remain buyer go forward mlnt pure-play antibiot compani approv product
commerci infrastructur could extract signific synergi deal antibiot launch late
compani current limit balanc sheet estim million cash
mdco deal like need addit cash year end past deal shown willing use mix
cash equiti debt financ
million except per share
includ result melinta reverse-merg cempra novemb
compani file gabelli compani estim
continu recommend investor hold melinta compani posit leader antibiot
market see near-term catalyst compani given typic slow launch trajectori
antibiot anticip melinta need rais cash year-end though compani could find non-
dilut fund ex-u licens deal vabomer mlnt share attract valu current
trade discount pmv per share lack clear catalyst ahead top-lin phase
cap data baxdela keep us rais recommend
ema decis approv vabomer cuti
top-lin phase data baxdela cap
ema decis approv baxdela absssi
million except per share
current market discount pmv
net present valu feder nol carryforward
 after-tax payment buy warrant option pmv
compani file gabelli compani estim
motif headquart london uk clinic stage pharmaceut compani develop iclaprim iv-
dose diaminopyrimidin antibiot iclaprim complet phase studi acut bacteri skin skin
structur infect absssi phase ii studi hospit acquir bacteri pneumonia/ventilator-associ
bacteri pneumonia hap/vap motif went public aim april price per share list
novemb ipo price per ordinari share
initi coverag motif hold recommend anticip iclaprim approv
absssi believ mtfb share fairli valu rel expect indic trade in-
line pmv per share estim sale million peak iclaprim sale
absssi million
find nephro-nich motif believ iclaprim find nich crowd absssi marketplac
patient risk acut kidney injuri aki compani estim nearli patient
absssi us annual moderate-to-sever renal impair drug success complet two
phase studi absssi expect file fda set potenti fda
approv decis earli
opportun hap/vap absssi lead indic iclaprim believ hap/vap could
greater opportun due fewer competitor sever patient popul phase studi
iclaprim show higher concentr lung compar plasma compani plan initi phase
studi hap/vap later year fund secur potenti top-lin data
buyer seller single-product compani motif would like seller consolid antibiot
market expect iclaprim modest uptak rel peer sale reach estim
million make difficult support commerci infrastructur larger compani
would abl integr iclaprim hospit portfolio also resourc support
hap/vap program meaning pipelin beyond new indic iclaprim make littl sens
motif remain independ compani follow iclaprim approv
million except per share
compani file gabelli compani estim
motif iclaprim
motif plc headquart london oper primarili us offic manhattan decemb
compani reach merger agreement nuprim gain right iclaprim condit
merger motif went public aim symbol mtfb april price per share follow
us list compani american depositori share ordinari share symbol
mtfb novemb ipo price per warrant symbol mtfbw warrant
exercis price per compani current million outstand ordinari share
despit list trade volum motif continu occur london aim
iclaprim intraven iv diaminopyrimidin antibiot inhibit dihydrofol reductas dhfr critic
bacteri enzym first develop roch potenti successor drug bactrim sulfamethoxazole/
trimethoprim antibiot nearli chf billion sale lifetim iclaprim potent dhfr
inhibitor trimethoprim activ trimethoprim-resist bacteria particularli
mutat drug sold arpida roch spin-out arpida complet two phase studi
mix result iclaprim vs linezolid complic skin skin structur infect csssi drug
reject fda time standard antibiot transit iclaprim chang hand
sever time follow fda reject arpida failur motif acquir base discuss
fda new guidelin antibiot motif initi two phase studi iclaprim vs vancomycin
absssi use fix dose twice-a-day vs weight-bas dose arpida studi clinic studi
met primari endpoint non-inferior earli clinic respons ecr
intent-to-treat popul common advers event headach iclaprim
vs vancomycin nausea vs fatigu vs nephrotox case
among iclaprim patient vs three case acut kidney injuri among vancomycin patient addit data
expect eccmid april
top-lin result reviv phase program iclaprim absssi
primari ecr etp
secondari clinic cure toc
ci confid interv ecr earli clinic respons etp earli time point intent-to-treat toc test cure
find nich nephrotox risk
motif plan file nda iclaprim anticip potenti fda approv earli drug
would enter crowd absssi market gener vancomycin current standard care mrsa
patient approxim market share altern like linezolid daptomycin also avail gener
four new drug approv sinc dalvanc sivextro orbactiv baxdela fifth
omadacyclin pend fda market absssi larg million hospit annual
market share new antibiot limit antibiot stewardship initi gener drug price
antibiot mrsa coverag treatment absssi
base full maximum cours therapi iv formul
payment allow medicar part databas compani file gabelli compani estim
motif believ iclaprim carv nich absssi market among patient risk acut kidney injuri
aki due renal impair estim patient total sever impair anoth
total moder impair nephrotox observ vancomycin dose adjust
recommend patient mild-to-sever renal impair assum brand price per cours
therapi would yield nearli million market opportun us estim iclaprim could
ultim captur approxim market peak sale million absssi
motif look expand indic iclaprim lung infect iclaprim show higher
concentr epitheli line fluid alveolar macrophag compar plasma phase studi
drug demonstr proof-of-concept hospit acquired/ventilator-associ bacteri pneumonia hap/vap
favor phase ii data vs vancomycin phase ii studi iclaprim higher rate clinic
cure vs risk death within day vs motif plan initi phase studi
fund secur top-lin data would expect number annual patient
hap/vap million gram-posit infect absssi million believ
repres attract market given limit therapi option sever diseas mortal risk
also believ product approv hap/vap could justifi premium price given timelin associ
indic estim valuat current exclud benefit hap/vap
addit hap/vap motif also evalu iclaprim treatment staphylococcu aureu lung infect
patient cystic fibrosi orphan drug indic indic still pre-clin develop
motif could elig non-dilut fund support initi clinic studi
estim valuat
expect slow uptak iclaprim absssi market due competit histor trend compar drug
need educ market drug potenti nich patient impair kidney function
estim sale reach million fourth year market give iclaprim launch trajectori
orbactiv million fourth year dalvanc million fourth year estim peak sale opportun
million absssi motif need addit cash support phase studi hap/vap launch
absssi though compani consid out-licens partner iclaprim model assum motif
commerci iclaprim contract sale forc base compani balanc sheet
septemb million cash million debt financ hercul novemb believ
motif need addit million support oper iclaprim approv
valuat base multipl iclaprim sale begin use sale multipl
discount valuat back annual assumpt also includ dilut financ activ
million equiti offer million equiti offer pmv declin time due dilut
cash burn compani reach ebitda-posit run-rat end
initi coverag motif hold recommend believ role iclaprim
absssi take time develop compani could target consolid within antibiot
market especi larger competitor will support hap/vap program key near-term catalyst
nda file accept potenti approv howev believ mtfb share fairli
valu would look attract entri point motif current trade in-lin pmv per
potenti fda submiss iclaprim absssi
initi phase hap/vap studi iclaprim
potenti fda approv iclaprim absssi
million except per share
current market discount pmv
after-tax payment buy warrant option pmv
compani file gabelli compani estim
nabriva headquart dublin ireland clinical-stag pharmaceut compani develop
lefamulin potenti first-in-class pleuromutilin system antibiot lefamulin current phase
treatment community-acquir bacteri pneumonia cap compani spun novarti
went public septemb ipo price per share
nabriva recent complet enrol second phase studi lefamulin leap follow posit data
leap septemb data leap posit data expect nabriva could file
fda approv second half
leap posit last septemb nabriva report posit result leap lefamulin iv-to-or
dose demonstr non-inferior moxifloxacin fda ema primari endpoint though
numer inferior overal side effect rate similar though lefamulin lower rate diarrhea
gi event vs slightli higher rate elev liver enzym consid data good enough
posit lefamulin fda approv pend result leap
await primari catalyst leap oral-onli studi lefamulin vs moxifloxacin cap studi
complet enrol patient decemb expect top-lin result posit
result would like lead nda file second half potenti approv
data readout binari event nabriva compani main catalyst note
valuat assum probabl lefamulin approv base posit result leap nabriva
end million per share cash provid potenti floor second phase
buyer seller believ nabriva like seller given compani size lack
pipelin beyond lefamulin cap nabirva phase ii data lefamulin absssi phase
data topic pleuromutilin neither program activ develop compani
plan focu hospit market lefamulin oral antibiot cap could also use
outpati set larger player antibiot market lack iv-to-or product cap
make lefamulin attract target compani could maxim drug commerci opportun
commun set compani recent licens right greater china roviant million
up-front plu million mileston royalti maintain global right
million except per share
ep adjust relfect pro-forma post-ipo share count
compani file gabelli compani estim
continu recommend nabriva lefamulin repres new class antibiot make rariti late-stag
antibiot develop compani still clinic risk leap data pend believ current
valuat allow signific upsid data posit leap data demonstr proof-of-concept
cap yet nbrv share trade pre-leap level vs declin
nbrv current trade discount pmv per share
top-lin data phase studi leap oral lefamulin cap
potenti fda submiss lefamulin cap
mid potenti fda approv lefamulin cap
million except per share
current market discount pmv
after-tax payment buy option pmv
compani file gabelli compani estim
paratek pharmaceut headquart boston clinical-stag pharmaceut compani two
tetracyclin antibiot complet phase develop omdacyclin develop acut
bacteri skin skin structur infect absssi commun acquir bacteri pneumonia cap
sarecyclin licens allergan us develop treatment acn
paratek file approv omadacyclin absssi cap assum fda accept file
would anticip pdufa date earli octob
label high degre confid omadacyclin approv probabl
see greater uncertainti regard label specif whether product approv oral-onli
dose cap oral-onli cap label would greatli enhanc market omadacyclin commun
set expect paratek initi focu hospit market regardless label compani
talk seek partner expand commun beyond year two commerci
advanc uti paratek advanc urinari tract infect uti program omadacyclin
recent initi phase ii studi cystiti compani plan initi second phase ii studi
complic uti acut pyelonephr ap later year paratek deliber
approach omadacyclin posit success rather rush phase program
believ potenti phase ii program support nda fda limit
popul pathway would provid upsid current estim uti approv current
believ uti could ultim largest market opportun omadacyclin drug
would offer oral altern quinolon
buyer seller peer seem fit cleanli one side buyer/sel line believ paratek
firmli middl omadacyclin profil lead drug support sale
infrastructur due dual indic once-daili iv-to-or dose strength omadacyclin
paratek manag team posit compani potenti buyer end million
cash plu addit million secondari offer januari monet opportun
sarecyclin royalti ex-u right omadacyclin side paratek still one-product
compani limit pipelin opportun beyond omadacyclin cap white space mani larger
antibiot player make omadacyclin potenti target acquisit ultim believ paratek
best option could deal similar melinta/medicin paratek acquir exist portfolio
larger competitor allergan exchang cash stock
million except per share
compani file gabelli compani estim
continu recommend paratek one favorit name antibiot sector given conveni dose
spectrum bacteri coverag multipl indic omadacyclin could one wide prescrib
brand antibiot believ omadacyclin posit paratek either buyer seller among
antibiot compani anticip two fda catalyst approv decis omadacyclin
sarecyclin current trade discount pmv per share
fda accept nda file omadacyclin
initi second phase ii studi omadacyclin uti
potenti fda approv omadacyclin absssi cap
potenti approv sarecyclin acn
ema file omadacyclin
potenti us launch omadacyclin
top-lin phase ii data omadacyclin cystiti
million except per share
current market discount pmv
net present valu feder nol carryfoward
 after-tax payment buy option pmv
compani file gabelli compani estim
tetraphas headquart watertown clinic stage pharmaceut compani focus develop
fully-synthet tetracyclin antibiot compani lead product eravacyclin broad spectrum tetracyclin
complet phase studi complic intra-abdomin infect ciai
rais recommend buy follow failur subsequ sell-off ttph
share share trade close year-end cash level million per share believ tetraphas
offer attract upsid potenti eravacyclin approv vs downsid risk
still aliv ciai complic urinari tract infect cuti program appear dead follow
failur eravacyclin much aliv treatment ciai fda accept nda
ciai pdufa date august eravacyclin two posit phase studi
indic signific safeti signal across entir ignit program anticip approv
year estim probabl serv signific catalyst ttph compani also anticip
approv decis ema file base data ciai
cushion ttph share trade slightli compani year-end cash posit
approxim per share compani also million feder net oper loss
carryforward even factor setback eravacyclin depress valuat recent
antibiot deal believ approv antibiot gram-neg coverag significantli greater
valu tetraphas current enterpris valu approxim million
buyer seller believ tetraphas seller given current valuat follow
result eravacyclin like still role antibiot commun iv-onli single-
indic ciai treatment drug-resist gram-neg infect believ justifi
cost commerci infrastructur sale fda approv would seem reason
approach buyer high degre confid approv would better serv buy
compani immedi preserv cash complet integr work ahead time launch us
million except per share
compani file gabelli compani estim
rais recommend tetraphas buy ttph appear oversold level anticip
approv eravacyclin august serv catalyst eravacyclin overal valu clearli diminish
loss oral dose cuti current level ttph becom recalibr risk/reward stori
clinic trial eravacyclin like near-term catalyst fda approv ciai strong balanc sheet
million cash ttph current trade discount pmv per share
fda pdufa date august eravacyclin ciai
potenti launch eravacyclin us
ema decis approv eravacyclin ciai
complet phase studi
million except per share
current market discount pmv
net present valu feder nol carryforward
 after-tax payment buy option pmv
compani file gabelli compani estim
kevin kedra research analyst prepar report herebi certifi view express report accur reflect
analyst person view subject compani secur research analyst receiv
direct indirect compens express specif recommend view report
